Quantification of amyloid-beta 40 in cerebrospinal fluid

N.A. Verwey, R. Veerhuis, H.A.M. Twaalfhoven, D. Wouters, J.J.M. Hoozemans, Y.J.M. Bollen, J. Killestein, M. Bibl, J. Wiltfang, C.E. Hack, P. Scheltens, M.A. Blankenstein

Research output: Contribution to journalArticleAcademicpeer-review

21 Citations (Scopus)


Background: Truncated forms and full-length forms of the amyloid-beta 40 (Aβ40) are key molecules in the pathogenesis of dementia, and are detectable in CSF. Reliable methods to detect these biomarkers in CSF are of great importance for understanding the disease mechanisms and for diagnostic purposes. Methods: VU-α-Aβ40, a monoclonal antibody (mAb) specifically detecting Aβ40, was generated and characterized by solid and fluid phase ELISA, surface plasmon resonance spectroscopy (SPRS), immunoprecipitation (IP), immunohistochemical and Western blot (WB) analysis. In addition, an ELISA with VU-α-Aβ40 as catching and 6E10 as detecting mAbs was set up and validated. This ELISA was used to measure Aβ40 in CSF of controls (N = 27), patients with Alzheimer's disease (AD; N = 20), frontotemporal lobe dementia (FTLD; N = 14), noninflammatory (N = 15) and inflammatory (N = 15) neurological conditions. Results: VU-α-Aβ40 specifically recognizes Aβ40 with high affinity (K
Original languageEnglish
Pages (from-to)57-66
JournalJournal of immunological methods
Issue number1-2
Publication statusPublished - 2009

Cite this